Aim: INVIDIa was a retrospective, multicenter study, exploring the clinical efficacy of influenza vaccine in 300 cancer patients undergoing immunotherapy. Overall survival (OS) was immature at the initial report. Methods: We reported the final OS analysis from the original study population and within subgroups. Results: Both at the univariate and multivariate analysis, the occurrence of influenza syndrome (IS) was significantly related to better OS in the overall population (OR: 0.53 [95% CI: 0.32-0.88]; p = 0.01). In the lung cancer subgroup, receiving flu vaccine and/or developing IS was related to better OS (p = 0.04). Within elderly patients, the flu vaccine was the main variable for the relative OS advantage (p = 0.05). Conclusion: Receiving the flu vaccine and/or developing IS was related to better OS within the INVIDIa population.
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study / Bersanelli, M., Buti, S., Banna, G.L., Giorgi, U.D., Cortellini, A., Rebuzzi, S.E., Tiseo, M., Fornarini, G., Mazzoni, F., Panni, S., Tursi, M.D., Marino, P.D., Rossetti, S., Rossi, E., Tomao, S., Luca, E.D., Soraru, M., Mucciarini, C., Atzori, F., Torre, L.L., et al.. - In: IMMUNOTHERAPY. - ISSN 1750-743X. - 12:2(2020), pp. 151-159. [10.2217/imt-2019-0180]
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study
Bersanelli M.;Buti S.;Tiseo M.;
2020-01-01
Abstract
Aim: INVIDIa was a retrospective, multicenter study, exploring the clinical efficacy of influenza vaccine in 300 cancer patients undergoing immunotherapy. Overall survival (OS) was immature at the initial report. Methods: We reported the final OS analysis from the original study population and within subgroups. Results: Both at the univariate and multivariate analysis, the occurrence of influenza syndrome (IS) was significantly related to better OS in the overall population (OR: 0.53 [95% CI: 0.32-0.88]; p = 0.01). In the lung cancer subgroup, receiving flu vaccine and/or developing IS was related to better OS (p = 0.04). Within elderly patients, the flu vaccine was the main variable for the relative OS advantage (p = 0.05). Conclusion: Receiving the flu vaccine and/or developing IS was related to better OS within the INVIDIa population.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
